83647-43-2

Usage

Uses

Used in Pharmaceutical Industry:
(3-bromo-2-methylphenyl)methanol serves as a valuable building block in the synthesis of a wide range of pharmaceutical compounds. Its bromine and hydroxyl functional groups contribute to the development of new drugs with diverse therapeutic properties.
Used as a Reagent in Organic Synthesis:
In organic synthesis, (3-bromo-2-methylphenyl)methanol acts as a reagent to introduce bromine and hydroxyl functional groups into target molecules. This capability enhances the reactivity and functionalization of organic compounds, facilitating the creation of new chemical entities with potential applications in various industries.
Used in Medicinal Chemistry Research:
(3-bromo-2-methylphenyl)methanol has been studied for its antioxidant and anti-inflammatory properties, making it a promising candidate for research in medicinal chemistry. Its potential to modulate biological processes and exhibit therapeutic effects positions it as a valuable compound for the development of novel pharmaceutical agents.
However, it is crucial to handle (3-bromo-2-methylphenyl)methanol with care, as it is a potent irritant. Proper safety measures should be taken to minimize the risk of harm during its use in research and industrial applications.

Upstream product

• 529-20-4 2-methylphenyl aldehyde 
• 103038-43-3 3-bromo-2-methyl-benzoic acid ethyl ester 
• 52780-15-1 3'-bromo-2'-methylbenzonitrile 
• 76006-33-2 3-bromo-2-methylbenzoic acid 
• 83647-42-1 3-amino-2-methylbenzyl alcohol 
• 99548-54-6 methyl 3-bromo-2-methylbenzoate 
• 83647-40-9 3-bromo-2-methylbenzaldehyde 
• 69321-60-4 2,6-dibromotoluene 

Downstream Products

• 154148-84-2 2-((3',4'-dimethoxyphenyl)methoxy)methyl-6-bromotoluene 
• 112299-62-4 1-bromo-3-(bromomethyl)-2-methylbenzene 
• 128366-50-7 2-(hydroxymethyl)-6-(1'-methyl-1'-(5''-imidazolyl)methyl)toluene 
• 148324-04-3 methyl 2-methyl-3-(1'-methyl-1'-(5''-imidazolyl)methyl)benzoate 
• 154148-89-7 2-(((3',4'dimethoxyphenyl)methoxy)methyl)-6-(1'-methylene-1'-(5''-imidazolyl)methyl)toluene 
• 154148-86-4 2-(((3',4'-dimethoxyphenyl)methoxy)methyl)-6-((5'-imidazolyl)methyl)toluene 
• 154148-87-5 2-(((3',4'dimethoxyphenyl)methoxy)methyl)-6-(1'-oxo-1'-(5''-imidazolyl)methyl)toluene 
• 154148-88-6 2-(((3',4'dimethoxyphenyl)methoxy)methyl)-6-(1'-hydroxy-1'methyl-1'-(5''-imidazolyl)methyl)toluene 
• 154148-90-0 2-(((3',4'dimethoxyphenyl)methoxy)methyl)-6-(1'-methyl-1'-(5''-imidazolyl)methyl)toluene 
• 154148-85-3 2-(((3',4'-dimethoxyphenyl)methoxy)methyl)-6-(1'-hydroxy-1'-(5''-imidazolyl)methyl)toluene 
• 128366-51-8 2-methyl-3-(1'-methyl-1'-(5''-imidazolyl)methyl)benzoic acid 
• 65276-20-2 2,3,2',3'-tetramethyl-bibenzyl 
• 92396-98-0 3,3'-Dibromo-2,2'-dimethyldiphenylethane 
• 101783-93-1 1,2-bis(3'-bromomethyl-2'-methylphenyl)ethane 

Relevant academic research and scientific papers

Molecular hybridization used to design and synthesize neo-tanshinlactone derivatives as PD-1/PD-L1 inhibitors

Four series of molecular hybrids (37 final products) of neo-tanshinlactone, a natural product extracted from Salvia miltiorrhiza Bunge, and known PD-1/PD-L1 interaction inhibitors were prepared as possible chemotherapeutic agents against triple negative breast cancer. Screening using a homogenous time-resolved fluorescence method resulted in three lead compounds (MZ52 IC50 74 ± 4 nM; MZ58 IC50 134 ± 17 nM; MZ61 IC50 225 ± 19 nM). With less T cell cytotoxicity and effects in activating CD8+ T cells in a T cell proliferation assay and a functionality experiment, MZ58 was selected as the best candidate for animal experiments. MZ58 exhibited antitumor effects in a subcutaneous transplantation tumor model as well as effects in reducing T cell exhaustion. In conclusion, after in vivo and in vitro experiments, we successfully acquired an effective candidate (MZ58) showing antitumor effects with low cytotoxicity toward T cells as well as the ability to activate CD8+ T cells and reduce T cell exhaustion.

Novel biphenyl derivative as well as preparation method and medical application thereof

The invention relates to the field of medicinal chemistry, and discloses biphenyl derivatives with PD-1/PD-L1 inhibitory activity as well as a preparation method and application of the biphenyl derivatives. The invention further discloses a composition containing the biphenyl derivative with the PD-1/PD-L1 inhibitory activity or the pharmaceutically acceptable salt of the biphenyl derivative and a pharmaceutically acceptable carrier of the biphenyl derivative, and application of the biphenyl derivative in preparation of a PD-1/PD-L1 inhibitor. The compound can be used for treating tumors.

Design, synthesis, evaluation, and SAR of 4-phenylindoline derivatives, a novel class of small-molecule inhibitors of the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) interaction

The blockade of the PD-1/PD-L1 immune checkpoint pathway with small molecules is an emerging immunotherapeutic approach. A novel series of 4-phenylindoline derivatives were synthesized, and their inhibitory activity against the PD-1/PD-L1 protein-protein interaction (PPI) was evaluated through a homogenous time-resolved fluorescence (HTRF) assay. Among them, A20 and A22 exhibited potent activity with IC50 values of 17 nM and 12 nM, respectively. Furthermore, A20 showed the promising inhibitory activity against the PD-1/PD-L1 interaction with the EC50 value of 0.43 μM in a co-culture model of PD-L1/TCR Activator-expressing CHO cells and PD-1-expressing Jurkat cells. Besides, the structure?activity relationships (SAR) of the novel synthesized 4-phenylindoline derivatives was concluded, and the binding mode of A22 with the PD-L1 dimer was analyzed by molecular simulation and docking, demonstrating that the N-atom in the side chain of indoline fragment could interact with the amino acid residue of the PD-L1 protein to lead to the potent inhibitory activity. This study provided a new insight for further drug design.

Heterocyclic substituted biphenyl compound as well as preparation method and application thereof

The invention discloses a heterocyclic substituted biphenyl compound as well as a preparation method and application thereof. According to the present invention, the compound can block the PD-1/PD-L1 signal pathway, and can be used as the immune checkpoint PD-1/PD-L1 small molecule inhibitor; and according to the compound disclosed by the invention, the metabolic stability is improved while the high binding rate with PD-L1 protein is maintained. A hydrophilic group is introduced to a heterocyclic ring, and the PD-1/PD-L1 inhibitory activity is improved.

Design, synthesis and biological evaluation of isoxazole-containing biphenyl derivatives as small-molecule inhibitors targeting the programmed cell death-1/ programmed cell death-ligand 1 immune checkpoint

Monoclonal antibodies targeting the programmed cell death-1/ programmed cell death-ligand 1 (PD-1/PD-L1) immune checkpoint have achieved enormous success in cancer immunotherapy. But the antibody-based immunotherapies carry a number of unavoidable deficie

Discovery of novel small-molecule inhibitors of pd-1/pd-l1 interaction via structural simplification strategy

Blockade of the programmed cell death 1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction is currently the focus in the field of cancer immunotherapy, and so far, several monoclonal antibodies (mAbs) have achieved encouraging outcomes in cancer tr

Discovery of 1,3,4-oxadiazole derivatives as potential antitumor agents inhibiting the programmed cell death-1/programmed cell death-ligand 1 interaction

Inhibition of the programmed cell death-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) interaction by small-molecule inhibitors is emerging cancer immunotherapy. A series of novel 1,3,4-oxadiazole derivatives were designed, synthesized, and evaluated for

A comparative study of the recent most potent small-molecule PD-L1 inhibitors: what can we learn?

Immune checkpoint inhibitors targeting the PD-1/PD-L1 pathway have become a “game-changer” in the cancer treatment. However, none of the small molecular inhibitors has been approved yet. To explore the advantages and disadvantages of various scaffolds, di

Addition of Fluorine and a Late-Stage Functionalization (LSF) of the Oral SERD AZD9833

Herein we describe our efforts using a late stage functionalization together with more traditional synthetic approaches to generate fluorinated analogues of the clinical candidate AZD9833. The effects of the addition of fluorine on the lipophilicity, permeability, and metabolism are discussed. Many of these changes were tolerated in terms of pharmacology and resulted in high quality molecules which reached advanced stages of profiling in the testing cascade.

Fused ring compound and application thereof (by machine translation)

The invention discloses a fused ring compound and application. The invention provides a compound, a pharmaceutically acceptable salt, a hydrate, a solvate, a metabolite, a stereoisomer, a tautomer or a prodrug. The compound I, provided by the invention, has the advantages of high activity, high bioavailability, stable medicine, oral administration, and the like. (by machine translation)